Intervention
sunitinib
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 15 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
15 shownBrain Mets - Capecitabine Plus Sunitinib and WBRTNCT00570908 · 2009-02-01
TERMINATEDSunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel ChemotherapyNCT00676650 · 2008-07-01
TERMINATEDIrinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung CancerNCT00695292 · 2008-06-01
COMPLETEDSunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung CancerNCT00620347 · 2008-03-01
COMPLETEDAn Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate CancerNCT00748358 · 2008-03-01
COMPLETEDSunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLCNCT00616109 · 2007-09-01
COMPLETEDEfficacy And Safety Of Sunitinib In Women With Advanced Breast CancerNCT00471276 · 2007-08-01
COMPLETEDA Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.NCT00428220 · 2007-07-01
COMPLETEDA Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib AloneNCT00457392 · 2007-07-01
COMPLETEDA Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)NCT00434356 · 2007-03-01
TERMINATEDA Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)NCT00434226 · 2007-03-01
TERMINATEDPhase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung AdenocarcinomaNCT00430261 · 2007-01-01
COMPLETEDA Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib AloneNCT00265317 · 2006-06-01
COMPLETEDA Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung CancerNCT00113516 · 2005-09-01
COMPLETEDStudy Of SU011248 In Combination With Docetaxel In Patients With Advanced CancerNCT00712504 · 2004-07-01
COMPLETEDCommon conditions
Non-Small Cell Lung Cancer3Lung Cancer2Metastatic Breast Cancer2Prostatic Neoplasms2Adenocarcinoma1Advanced Breast Cancer1Advanced Gastric Cancer1Advanced Solid Tumors1Advanced/Metastatic Non-Small Cell Lung Cancer1Breast Cancer1Breast Neoplasms1Carcinoma, Non-Small Cell Lung1Carcinoma, Non-Small-Cell Lung1Disease-Free Survival1Extensive-Stage Small Cell Lung Cancer1Gastrointestinal Stromal Tumor1Hepatocellular Carcinoma1Metastatic Castration Resistant Prostate Cancer1Metastatic Renal Cell Cancer1Neoplasms, Hormone-Dependent1Non Small Cell Lung Cancer1Pancreatic Islet Cell Carcinoma1Pancreatic Neuroendocrine Tumor1Small Cell Lung Cancer1Survival Rate1
Leading sponsors
Trial status mix
COMPLETED11
TERMINATED4
Phase mix
PHASE211
PHASE32
NA1
PHASE11
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.